Neuro-Bio was mentioned on 2 articles on August the 27th on Mergermarket, an ACURIS company.

Please find here the full article on Neuro-Bio’s fundraising plans: Neuro-Bio seeks to raise GBP 10m Series C by 1H22 for Alzheimer’s peptide drug – CEO _ Mergermarket

And this is a small extract of the analysis piece published in regard Neuro-Bio’s new pathway: “the UK’s Neuro-Bio has discovered a novel 14 amino acid bioactive peptide (T14) that has been shown to be a potential key driver of neurodegeneration. T14 can also be measured in the blood – which will facilitate testing for the disease. Companies with this approach will garner the interest from major diagnostic players that can use the biomarker in other applications as a companion diagnostic, thereby enhancing a target company’s valuation.”